SCHEMBL5146672

SCHEMBL5146672

Cc1ccc(C(=O)O)cc1-c1ccc(C(=C2NC(=O)NC2=O)c2ccccc2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.49
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
POLB P06746 7/20 0.49
KDM4E B2RXH2 7/20 0.49
MAPT P10636 6/20 0.49
CTDSP1 Q9GZU7 6/20 0.49
L3MBTL1 Q9Y468 6/20 0.49
TDP1 Q9NUW8 5/20 0.48
HPGD P15428 4/20 0.48
APEX1 P27695 4/20 0.48
RECQL P46063 2/20 0.48
PSMD14 O00487 1/20 0.48
MMP2 P08253 1/20 0.48
DNMT1 P26358 1/20 0.48
PPM1G O15355 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN7 P35236 1/20 0.40
PTPN5 P54829 1/20 0.40
PTPRO Q16827 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145164 0.76 KDM4E (0.48) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5145320 0.75 MEN1 (0.46) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5143034 0.73 POLB (0.65) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5143032 0.73 POLB (0.65) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5145205 0.72 PPM1G (0.45) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5145012 0.69 MEN1 (0.42) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5144944 0.68 POLB (0.43) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5147463 0.68 MEN1 (0.44) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5147466 0.68 MEN1 (0.44) ALDH1A1MEN1KMT2APOLBKDM4E
SCHEMBL5144975 0.68 TTR (0.46) ALDH1A1MEN1KMT2APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 ALDH1A1 2413/4885MEN1 4004/4885KMT2A 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.